122 related articles for article (PubMed ID: 23688047)
1. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
Freeman C; Keane N; Swords R; Giles F
Expert Opin Pharmacother; 2013 Jul; 14(10):1417-27. PubMed ID: 23688047
[TBL] [Abstract][Full Text] [Related]
2. Vosaroxin : a novel antineoplastic quinolone.
Abbas JA; Stuart RK
Expert Opin Investig Drugs; 2012 Aug; 21(8):1223-33. PubMed ID: 22724917
[TBL] [Abstract][Full Text] [Related]
3. The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.
Paubelle E; Zylbersztejn F; Thomas X
Expert Opin Drug Discov; 2017 Jul; 12(7):747-753. PubMed ID: 28504025
[TBL] [Abstract][Full Text] [Related]
4. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Hotinski AK; Lewis ID; Ross DM
Expert Opin Pharmacother; 2015 Jun; 16(9):1395-402. PubMed ID: 25958926
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ; Ravandi F
Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
Nijenhuis CM; Lucas L; Rosing H; Huitema ADR; Mergui-Roelvink M; Jamieson GC; Fox JA; Mould DR; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Aug; 35(4):478-490. PubMed ID: 28138829
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Jamieson GC; Fox JA; Poi M; Strickland SA
Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
[TBL] [Abstract][Full Text] [Related]
8. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Stuart RK; Cripe LD; Maris MB; Cooper MA; Stone RM; Dakhil SR; Turturro F; Stock W; Mason J; Shami PJ; Strickland SA; Costa LJ; Borthakur G; Michelson GC; Fox JA; Leavitt RD; Ravandi F
Br J Haematol; 2015 Mar; 168(6):796-805. PubMed ID: 25403830
[TBL] [Abstract][Full Text] [Related]
9. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
[TBL] [Abstract][Full Text] [Related]
10. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
[TBL] [Abstract][Full Text] [Related]
11. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Freeman CL; Swords R; Giles FJ
Expert Rev Hematol; 2012 Feb; 5(1):17-26. PubMed ID: 22272701
[TBL] [Abstract][Full Text] [Related]
12. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton CB; Ravandi F
Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II inhibitors in AML: past, present, and future.
Economides MP; McCue D; Borthakur G; Pemmaraju N
Expert Opin Pharmacother; 2019 Sep; 20(13):1637-1644. PubMed ID: 31136213
[No Abstract] [Full Text] [Related]
14. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Pigneux A; Horst HA; Récher C; Klimek VM; Cortes JE; Carella AM; Egyed M; Krug U; Fox JA; Craig AR; Ward R; Smith JA; Acton G; Kantarjian HM; Stuart RK
Haematologica; 2018 Nov; 103(11):e514-e518. PubMed ID: 29794146
[No Abstract] [Full Text] [Related]
15. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Dennis M; Russell N; Hills RK; Hemmaway C; Panoskaltsis N; McMullin MF; Kjeldsen L; Dignum H; Thomas IF; Clark RE; Milligan D; Burnett AK
Blood; 2015 May; 125(19):2923-32. PubMed ID: 25805811
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
17. Amonafide: a potential role in treating acute myeloid leukemia.
Allen SL; Lundberg AS
Expert Opin Investig Drugs; 2011 Jul; 20(7):995-1003. PubMed ID: 21591994
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
19. Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Feldman EJ
Best Pract Res Clin Haematol; 2011 Dec; 24(4):523-6. PubMed ID: 22127315
[TBL] [Abstract][Full Text] [Related]
20. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H; Yang D
Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]